Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jhansi Mead

Child & Adolescent Psychiatry Richmond, VA Medical Doctor

NPI 1801973805 CMS profile 1155259

2301 N Parham Rd Ste 5, Richmond, VA 23229

Open in the dashboard

General payments

$2,316

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jhansi Mead of Richmond, VA is reported in the CMS Open Payments database as having received $2,316 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $873 39
2024 General $975 44
2023 General $118 7
2022 General $18 1
2021 General $15 1
2020 General $97 5
2019 General $219 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jhansi Mead
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Jhansi Mead were reported at $873. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Jhansi Mead Child & Adolescent Psychiatry median Middle half National median
2019 $219 $129 $42–$419 $163
2020 $97 $81 $28–$226 $114
2021 $15 $115 $31–$326 $132
2022 $18 $124 $40–$382 $149
2023 $118 $130 $45–$420 $160
2024 $975 $141 $42–$490 $164
2025 $873 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $471 14 payments
  2. Vanda Pharmaceuticals Inc. $265 11 payments
  3. Alkermes, Inc. $216 10 payments
  4. Neurocrine Biosciences, Inc. $214 10 payments
  5. Corium, Inc. $163 6 payments
  6. ITI, Inc. $153 9 payments
  7. Otsuka America Pharmaceutical, Inc. $107 5 payments
  8. Lundbeck LLC $100 6 payments
  9. Ironshore Pharmaceuticals Inc. $82 4 payments
  10. Axsome Therapeutics, Inc. $81 4 payments
  11. Other $464 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,316 105 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $471 14 payments
  2. FANAPT $265 11 payments
  3. LYBALVI $216 10 payments
  4. ARISTADA Cns $198 9 payments
  5. ARISTADA Cns $198 9 payments
  6. ARISTADA Cns $198 9 payments
  7. ARISTADA Cns $198 9 payments
  8. INGREZZA $179 8 payments
  9. Azstarys $163 6 payments
  10. CAPLYTA $137 8 payments
  11. Other $1,037 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record